Targeted chemotherapy with poly-ADP ribose polymerase inhibitors and platinum-based agents for high-risk individuals with germline BRCA/PALB2 variants can potentially improve progression-free survival. Finally, differences in tumor biology may contribute to the wide range of reported PDAC survival. This evidence concerns the gene PALB2 and neoplasm.